txmd-8k_041913.htm

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported): April 19, 2013
 
TherapeuticsMD, Inc.
(Exact Name of Registrant as Specified in its Charter)
 
Nevada
  
000-16731
  
87-0233535
(State or Other
Jurisdiction of Incorporation)
  
(Commission File Number)
  
(IRS Employer
Identification No.)

 
951 Broken Sound Parkway NW, Suite 320
Boca Raton, FL 33487
(Address of Principal Executive Office) (Zip Code)
 
Registrant's telephone number, including area code:  (561) 961-1911
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
 
£
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
£
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
£
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
£
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 

Item 8.01.
Other Events.
 
On April 19, 2013, TherapeuticsMD, Inc. (the “Company”) was notified that the Company’s common stock has been approved for listing on the NYSE:MKT and is expected to start trading on the NYSE:MKT on Tuesday, April 23, 2013 under its ticker symbol TXMD. A copy of the press release reporting this listing is attached hereto as Exhibit 99.1.

Item 9.01.
Financial Statements and Exhibits.
  
 
 
(d)
Exhibits.
  
 
    Exhibit  
 
 
 Number
Description
       
 
 
99.1
 Press Release from TherapeuticsMD, Inc., dated April 22, 2013, entitled “TherapeuticsMD Announces Trading of its Common Stock on the NYSE:MKT under Symbol ‘TXMD’”.
 
 
 
 
 
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date:  April 23, 2013
 THERAPEUTICSMD, INC.
     
     
  By: 
    /s/ Daniel A. Cartwright
   
Name:  Daniel A. Cartwright
   
Title:    Chief Financial Officer
 
 
 
 
 
 

EXHIBIT INDEX
 
    Exhibit  
    Number
Description
       
 
 
99.1
 Press Release from TherapeuticsMD, Inc., dated April 22, 2013, entitled “TherapeuticsMD Announces Trading of its Common Stock on the NYSE:MKT under Symbol ‘TXMD’”.